GT Biopharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GTBP Nasdaq 2836 www.gtbiopharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for GT Biopharma, Inc.

GT Biopharma Reports First Quarter 2026 Financial Results - May 15th, 2026 6:00 am
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors - May 14th, 2026 6:30 am
EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types - May 14th, 2026 6:16 am
Replays from RedChip's Biotech Investor Conference Now Available - Apr 20th, 2026 9:00 am
RedChip's April 16 Virtual Investor Conference to Highlight Companies Driving the Next Wave of Biotech Innovation - Apr 10th, 2026 10:55 am
GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know - Mar 16th, 2026 10:00 am
GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Mar 12th, 2026 7:55 am
GT Biopharma to Participate in the 38th Annual Roth Conference - Mar 11th, 2026 5:00 am
GT Biopharma Reports Full Year 2025 Financial Results - Mar 2nd, 2026 5:00 am
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference - Feb 17th, 2026 5:30 am
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3 - Feb 3rd, 2026 6:30 am
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers - Jan 15th, 2026 6:30 am
Stocks & Markets Podcast: Biotech CEO reveals the science of humane cancer treatment - Dec 8th, 2025 2:28 pm
GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials - Nov 19th, 2025 6:00 am
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 14th, 2025 7:00 am
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies - Oct 23rd, 2025 7:00 am
EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers - Oct 8th, 2025 6:31 am
GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit - Oct 6th, 2025 7:00 am
GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Sep 4th, 2025 5:00 am
GT Biopharma Reports Second Quarter 2025 Financial Results - Aug 14th, 2025 2:05 pm